Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

Clinical Microbiology and Biomedical Research: Bridging the Gap between the Lab and the Clinic

Dr. Nivaedhitha Mohan Kumar, Dr. Maivannan Nandhagopal* and Dr. P. Neelusree

Department of Microbiology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai 602105, Tamil Nadu, India.

*Corresponding author:

Maivannan Nandhagopal, Department of Microbiology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai 602105, Tamil Nadu, India.

(Received: 04 August 2023 Revised: 12 September Accepted: 06 October)

KEYWORDS

Clinical microbiology, biomedical research, diagnostics, antibiotic resistance, vaccines, emerging diseases, translational research

ABSTRACT:

The relationship between clinical microbiology and biomedical research is an essential nexus in modern healthcare, where laboratory discoveries and scientific insights translate into practical applications at the patient's bedside. Biomedical research has catalyzed groundbreaking developments in microbial diagnostics, revolutionizing microbial identification through advanced techniques such as PCR-based assays and next-generation sequencing. Another vital aspect of this synergy is the battle against antibiotic resistance. Biomedical research has unveiled the intricate mechanisms underlying resistance, paving the way for personalized treatments and novel antibiotics. Vaccines and immunotherapies also owe their success to collaborative efforts, as researchers in these fields continuously push the boundaries of disease prevention and treatment. Genomic research, epidemiological studies, and surveillance systems play a pivotal role in tracking and combatting new and evolving threats. Translational research, bridging laboratory discoveries and clinical applications, is the cornerstone of this partnership. Despite its many successes, challenges like regulatory obstacles and ethical considerations persist. Striking a balance between research progress and ethical responsibilities remains an ongoing challenge. The fusion of clinical microbiology and biomedical research represents an integral collaboration aimed at enhancing our understanding of infectious diseases and the quality of patient care. As healthcare evolves, this synergy will remain central in addressing microbial infections and emerging diseases, underscoring the power of interdisciplinary collaboration in advancing medical science and safeguarding public health.This review delves into the dynamic interplay between these two fields and their crucial role in advancing medical science and patient care.

Introduction:

Clinical microbiology and biomedical research are two domains that are intertwined and have significant roles in healthcare. Clinical microbiology is concerned with the diagnosis, characterisation, and management of microbial infections in patients, whereas biomedical research is concerned with the discovery and development of new diagnostic tools, therapeutic techniques, and insights into disease causes [1,2]. Clinical microbiology is a rapidly developing and vital profession that must constantly adapt to the changing landscape of infectious diseases, novel pathogens, and technological advancements. It is a pillar of contemporary medicine, supporting patient treatment as well as public health initiatives to battle infectious diseases. Biomedical research is a large and dynamic subject that includes scientific inquiries into the molecular mechanisms behind health, sickness, and medical conditions [3,4]. It is critical to the advancement of medical knowledge, the improvement of healthcare practices, and the advancement of innovation in the healthcare and pharmaceutical industries. Clinical microbiology and biomedical research have a symbiotic relationship that is critical for

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

training the next generation of scientists and healthcare workers. It exposes students to the practical applications of their research, ensuring that they have a comprehensive awareness of infectious diseases [5].

Biomedical research frequently results in the creation of more accurate and rapid diagnostic methods, which assist clinical microbiology [6]. For example, advances in molecular diagnostic tools enable clinical microbiologists to identify pathogens more rapidly and precisely, resulting in more successful treatment decisions. Biomedical research helps to find novel antibiotics, antivirals, and immunotherapies [7,8]. These results are critical in clinical microbiology, assisting physicians in the fight against antibiotic-resistant bacteria and offering patients with novel treatment options. The continued partnership allows for the detection of growing resistance patterns [9]. Biomedical research aids in the understanding of the mechanisms underlying microbial drug resistance [10]. This understanding enables more targeted therapies, minimizing antibiotic usage and resistance transmission, and is critical for proactive infection control efforts [11]. It also aids in the development of new medicines or alternative therapeutic approaches [12]. Vaccine development relies heavily on biomedical research [13]. Vaccination has considerably reduced the prevalence of many infectious diseases and has even paved the door for novel vaccine technologies such as mRNA-based vaccines[14]. Combining the knowledge and resources of clinical microbiologists and biological researchers encourages a collaborative and data-sharing environment[15]. This increases communal knowledge in both domains and speeds up advancement. Precision medicine techniques in the management of infectious diseases are enabled by the merging of clinical microbiology and biomedical research. Treatments that are tailored to a patient's specific infection and susceptibility profiles can result in more effective outcomes [16]. Collaborative approaches aid in the resolution of ethical and regulatory difficulties by generating talks about topics such as data protection and the responsible use of developing technologies [17].

The link between clinical microbiology and biomedical research is critical for One Health, which recognizes the interdependence of human, animal, and environmental health [18]. This strategy is critical for dealing with zoonotic illnesses and environmental issues that affect human health. Regular communication and collaboration among these sectors promotes continuous improvement. Finally, integrating clinical microbiology and biomedical research is about delivering the best possible treatment for patients [19]. It enables healthcare practitioners to provide individualized, evidence-based treatment that takes into account the unique characteristics of each patient and their infection, resulting in improved clinical outcomes. Researchers and clinicians exchange feedback, insights, and findings, resulting in iterative advances in diagnosis, therapies, and prevention techniques. This review looks at how these professions interact and how they work together to progress medical science and enhance patient care.

1. Advancements in Diagnostics:

Diagnostics is one of the most significant contributions of biomedical science to clinical microbiology. Biomedical research has fueled the development of novel diagnostic tools such as PCR-based assays, next-generation sequencing, and sophisticated imaging methods[20,21]. These breakthroughs have increased the speed and accuracy of microbiological identification, resulting in more precise and prompt therapeutic decisions [22]. The incorporation of these technologies in clinical laboratories has allowed healthcare workers to identify pathogens more quickly, customize therapies more efficiently, and track illness development more precisely. These diagnostic advances not only increase our ability to diagnose infectious diseases, but they also help with tailored medication, early disease identification, and better patient outcomes. They are critical to the interaction of clinical microbiology and biomedical research, allowing for a better knowledge of diseases and directing the development of more tailored treatments [23]. Table 1 lists some of the most significant advancements.

S.No	DIAGNOSTIC TECHNIQUE		FEATURES
1.	**Molecular Diagnostics**	Polymerase Chain Reaction (PCR)	• Used to amplify and detect nucleic acid sequences of pathogens.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

			• Offers high sensitivity and specificity for identifying bacteria, viruses, and genetic markers[23].
		Next-Generation Sequencing (NGS)	• Allows for the rapid and comprehensive sequencing of genetic material. • Used for pathogen identification and whole-genome sequencing [24].
2.	**Serological Assays**	Enzyme-Linked Immunosorbent Assay (ELISA)	Used for detecting antibodies or antigens, including those related to infectious diseases[25].
3.	**Rapid Point-of-Care Tests**	Lateral Flow Assays	They provide quick results and are commonly used for diagnosing infectious diseases like HIV, malaria, and strep throat[26].
4.	**Immunohistochemistry (IHC)**	• used for tissue-based diagnostics like cancer. • allows the detection of specific proteins or antigens within tissue samples[27].	
5.	**Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)**	• Used for rapid and precise identification of microorganisms. • It is particularly valuable in clinical microbiology for bacterial and fungal identification[27].	
6.	**Digital Pathology**	• Involves scanning and analyzing tissue samples digitally. • It enables remote consultations, automated image analysis, and the creation of comprehensive digital archives for research and diagnostics[28].	
7.	**Biosensors**	• Used for real-time detection of specific biomolecules. • They can be employed in infectious disease diagnostics, monitoring glucose levels in diabetes, etc[29].	
8.	**Genomic and Proteomic Profiling**	These techniques involve the comprehensive analysis of an individual's genetic and protein profile, aiding in the diagnosis and personalized treatment of diseases[30].	
9.	**Metabolomics and Microbiomics**	They involve the study of small molecules and the microbiome, respectively. They provide valuable insights into disease mechanisms and can aid in diagnostics[31].	
10.	**Artificial Intelligence (AI) and Machine Learning**	AI algorithms can analyse vast datasets, including medical images and patient records and this aids in the diagnosis and prognosis of diseases[32].	

Table 1: Important advancements in diagnostics

2. Understanding Antibiotic Resistance:

Understanding antibiotic resistance is crucial in clinical microbiology and biomedical research because it has a direct influence on our ability to treat infectious infections. When microorganisms (bacteria, fungi, viruses) evolve methods to withstand the effects of antibiotics, these medications become less effective or ineffective[33].Antibiotic resistance has risen to the

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

level of a worldwide health crisis. Biomedical research has been critical in understanding the processes underlying this resistance and developing new therapeutic strategies[34]. This research has revealed the complicated interactions between bacteria and medications, leading to the creation of novel antibiotics and the concept of customized medicine in the treatment of infectious diseases [35]. This multidisciplinary approach guarantees that patients receive the most effective therapy while reducing antibiotic misuse [36].

Biomedical study looks on the numerous mechanisms that lead to antibiotic resistance. This includes researching the genetic alterations that allow bacteria and other organisms to tolerate antibiotic exposure [37]. To understand how resistance arises, researchers investigate themes like as mutation, horizontal gene transfer, and efflux pumps. Large-scale epidemiological studies are conducted by biomedical researchers to follow the frequency and spread of resistant bacteria [38, 39]. This contributes to a better understanding of resistance dynamics, such as the origin and spread of resistant genes and organisms. Researchers can now sequence the genomes of bacteria and find genetic markers linked with resistance because to advances in genomics and bioinformatics [40]. Studies in comparative genomics aid in determining the genetic basis of resistance mechanisms [41]. Antibiotics are also studied for their pharmacokinetics (how the body reacts to the drug) and pharmacodynamics (how the drug affects the microbe). This study sheds light on how various medications work, how microorganisms respond, and how resistance can develop under varied situations [42]. Understanding the characteristics of antibiotics requires biomedical study. This includes investigating antibiotics' mechanisms of action and how resistance may affect their efficacy. It is critical to understand the physiology and genetics of bacteria. This research gives insights into how bacteria can adapt to antibiotic exposure and evolve resistance tactics, such as biofilm formation or metabolic pathway alteration[43]. In vitro and in vivo models are also used by biomedical researchers to replicate infection scenarios and explore the dynamics of antibiotic resistance[44]. These models aid in determining the efficacy of various antibiotics and treatment regimens. Antibiotic resistance research activities are focused on creating new medicines and alternative therapies[45]. Biomedical researchers look into new medication targets, drug repurposing, and alternative antibacterial agents[46].They also look into precision medicine approaches, which adapt medicines to specific patients based on their genetic profile. This tailored strategy has the potential to improve treatment outcomes while reducing resistance development.Biomedical research informs public health policies about antibiotic use, surveillance, and antibiotic resistance management[47]. These regulations aim to reduce the spread of resistant strains while also encouraging prudent antibiotic use.

Antibiotic resistance is a serious global health concern, and biomedical research is at the forefront of understanding it. Biomedical researchers make major contributions to the ongoing war against antibiotic resistance by uncovering the intricacies of resistance mechanisms and devising novel tactics.

3. Advances in Vaccines and Immunotherapy:

Vaccines and immunotherapies have tremendously benefited from biomedical research[48]. These methods have altered infectious disease prevention and treatment. Vaccines not only prevent a wide range of diseases, but they also provide as a platform for cutting-edge research into therapeutics such as mRNA-based vaccines and other immunomodulatory approaches[49]. This collaboration between clinical microbiology and biomedical science is the driving force behind the pathogen-fighting effort. Vaccine and immunotherapy advancements are critical components of biomedical research because they serve a critical role in the prevention and treatment of a wide range of infectious diseases and some types of cancer. Biomedical research gives a thorough understanding of pathogen biology and genetics[50]. This knowledge is critical for determining the best vaccine targets and antigenic components. To find the most effective antigens for vaccine production, researchers use modern approaches such as genomics and proteomics[51]. This data informs the selection of antigens that elicit a high immune response. Biomedical research also looks into new adjuvants and vaccination formulations to improve vaccine efficacy and safety. These research seek to strike the optimal balance between immune activation and adverse effects. Vaccine platform research, such as viral vectors, mRNA technology, and recombinant proteins, enables the development of novel vaccines. These platforms

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

provide for greater flexibility in the development of vaccinations for various diseases. Clinical trials are an important component in vaccine development [52]. To assess vaccination safety and efficacy, biomedical researchers conduct rigorous clinical trials. This procedure aids in the identification of the most prospective candidates for licensure. Disease modeling and epidemiological studies are also used in biomedical research to anticipate vaccination impact and estimate the potential for disease eradication or control [53]. Vaccine delivery system research, such as microneedles, nanoparticles, and oral vaccines, improves the efficacy of vaccination programs and promotes worldwide vaccine distribution. Biomedical research is especially important in immunotherapy (Figure 1), with a particular emphasis on personalized medications, cancer treatments, autoimmune illnesses, and so on, and has demonstrated expertise in prevention and therapeutic measures.



Fig 1: Applications of Biomedical Research in Immunotherapy

4. Monitoring and Responding to Emerging Infectious Diseases:

Emerging infectious diseases can now be identified and characterized more quickly thanks to biomedical research [54]. Monitoring the spread of novel infections requires genomic research, epidemiological investigations, and improved surveillance technologies. This collaboration has been especially visible in current global health crises, as clinical microbiologists and researchers work together to study, track, and confront dangers like new viruses or drug-resistant strains[55].Monitoring and responding to emerging infectious illnesses is an important part of biomedical research because it is necessary for understanding, containing, and minimizing the impact of newly found pathogens. Among the applications are:

5.1 Surveillance and Detection:

Early warning systems for new infectious diseases are being developed by biomedical researchers. This includes ongoing clinical case monitoring, laboratory testing, and epidemiological investigations.For identifying novel infections and understanding their genetic makeup, improved genomics and next-generation sequencing approaches are critical [56]. Biomedical research also aids in the identification of genetic markers and evolutionary characteristics of new infections.Biomedical research is also concerned with zoonotic diseases, which are infections spread from animals to people [57]. Understanding these diseases necessitates the collaboration of virologists, epidemiologists, ecologists, and veterinarians.The study of vector-borne diseases such as malaria, Zika, and Lyme disease is critical for establishing efficient preventative and control strategies [58]. Understanding disease vector biology is critical for these efforts.

5.2 Public Health Response:

Diagnostic assays for new pathogens are developed and refined by biomedical researchers. Rapid and accurate diagnostic methods are critical for identifying and containing cases [59]. Epidemiology research aids in tracking the spread of infectious diseases, identifying risk factors, and evaluating the effectiveness of control measures [60]. Biomedical research influences public health initiatives for disease prevention and is also critical in the development of vaccines for new diseases[61]. Researchers in this sector are also looking at antiviral and antibacterial drugs that are effective against new diseases. This discovery is critical for therapeutic choices, especially in the absence of vaccinations.Understanding the human immune response to new diseases is critical for developing vaccines and treatment strategies[62]. Research aids in the identification of correlates of protection and the possibility of reinfection.

5.3 Global Collaboration:

Biomedical experts work with colleagues from all over the world to share data and findings about new infectious illnesses. Global research networks are critical for understanding pathogen global distribution and evolution[63].Transparency and collaboration in monitoring and responding to emerging infectious illnesses are enhanced by open access to research data, scientific publications, and real-time data-sharing platforms[64]. The One Health method is incorporated into biomedical research, which recognizes the connection of human, animal, and environmental health. This method is critical for understanding and addressing zoonotic diseases, as well as the environmental factors that influence disease emergence.Biomedical research is critical to our ability to effectively respond to developing infectious illnesses. It equips researchers with the knowledge and tools they need to study the biology of novel infections, develop diagnostics and cures, and inform public health policies. The speedy reaction to new diseases, such as the COVID-19 pandemic, emphasizes the importance of biomedical research in ensuring global health.

5. Translational Research:

Translational research bridges the gap between laboratory findings and clinical application, and it is the foundation of the clinical microbiology-biomedical research link[65]. It ensures that scientific advances result in tangible advantages for patients. This process comprises therapeutic intervention development, diagnostic method validation, and the establishment of best practices in healthcare[66]. Such translational research is critical in addressing real-world difficulties in microbial infection management.It entails translating scientific knowledge into practical advantages for patients and the general good. The following are some examples of translational research related to biomedical research:

6.1 Understanding Disease Mechanisms:

Biomedical research establishes the framework for translational research by elucidating fundamental illness mechanisms such as genetic, molecular, and cellular processes [67].Translational research is based on the identification of specific molecular targets and disease pathways [68]. These targets are then used to guide drug development and therapy techniques.

6.2 Development of Interventions:

Pharmaceutical and therapy development is aided by biomedical research. Translational research assesses the efficacy and safety of these discoveries in clinical

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

trials[69].Translational research encompasses the creation of biological therapies that have the potential to change medical treatments, such as monoclonal antibodies, gene therapies, and stem cell therapies[70].Translational research enables individualized medicine by translating genetic and molecular knowledge from biomedical research. It customizes therapy for individual patients depending on their specific profiles.Translational research looks into combination therapy, which may involve combining various pharmaceuticals or treatment methods to improve therapeutic outcomes[71].

6.3 Clinical Testing and Validation:

Translational research plans and implements clinical studies to evaluate the safety and efficacy of new therapies and interventions [72]. It is the crucial stage in which laboratory findings are validated in a clinical setting.Biomedical research influences the design and execution of phase I, II, and III clinical trials, with each phase serving a unique purpose in the evaluation of therapies.

6.4 Public Health Impact:

Translational research generates the evidence required for evidence-based medicine, which informs clinical practice and public health policies.Translational research findings are critical for securing regulatory approval for new medications, treatments, and medical devices[73].

6.5 Diagnostics and Biomarkers:

Potential biomarkers and diagnostic tools are discovered through biomedical research. Translational research verifies and improves diagnostic tests for use in clinical settings[74]. Translational research focuses on illness detection in order to provide prompt intervention and better patient outcomes.

6.6 Education and Training:

Translational research is critical for training the next generation of scientists and healthcare providers. It introduces them to the therapeutic uses of scientific discoveries[75].

6.7 Implementation in Practice:

Translational research helps to produce clinical standards and protocols that advise healthcare practitioners about the optimal patient care practices. The ultimate goal of translational research is to improve patient outcomes and healthcare quality [76]. It assures that scientific advances result in measurable benefits for individuals and populations.The collaboration of biomedical and translational research is critical for progressing medical knowledge and ensuring that laboratory discoveries are converted into real-world applications that benefit patients, healthcare systems, and public health.

6. Challenges:

Despite numerous accomplishments, several hurdles remain in connecting clinical microbiology and biomedical research.

7.1 Antibiotic Resistance: The increasing rise of antibiotic-resistant bacteria presents a significant concern. To detect and manage these resistant bacteria, clinical microbiology must constantly change, necessitating continuing research and development of new diagnostics and treatments[77].

7.2 Emerging Infectious Diseases: Identifying and responding to emerging infectious illnesses, such as new viruses and pandemics, is a big problem. There is a need for rapid diagnosis, treatment alternatives, and vaccine development[78].

7.3 Inadequate Resources: Many clinical microbiology laboratories, particularly those in resource-constrained settings, encounter obstacles due to insufficient infrastructure, equipment, and qualified workers, which impedes successful diagnosis and research[79].

7.4 Diagnostic Delays: Delays in diagnostic results can have an influence on patient care as well as public health reactions. Reducing test result turnaround times is a continuing challenge[80].

7.5 Quality Control and Standardization: It might be difficult to ensure the accuracy and uniformity of diagnostic testing between laboratories. Standardization is required for consistent results[81].

7.6 Data Privacy and Security: In clinical microbiology, the handling of patient data and the protection of patient privacy are key ethical and legal concerns[82]. It is critical to ensure data security.

7. Ethical Considerations:

Ethical considerations in biomedical research can be challenging due to several factors and complexities such as:

8.1 Informed Consent: Patients must offer informed consent for diagnostic testing and research involvement, according to researchers and healthcare providers. This includes discussing the procedures' aims as well as any potential risks[83].

8.2 Data Privacy and Confidentiality: Ethical rules require stringent patient information security and data confidentiality, ensuring that sensitive medical information is not disclosed without consent[84].

8.3 Patient Autonomy: Giving patients the right to make informed decisions regarding their healthcare and research participation is part of respecting patient autonomy. This includes the ability to refuse treatment or study participation[85].

8.4 Beneficence and Non-Maleficence: Researchers and doctors must strike a balance between doing good (beneficence) and preventing harm (non-maleficence). This includes assessing the advantages and disadvantages of diagnostic tests and treatments[86].

8.5 Ethical Use of Research Findings: The ethical application of scientific findings is critical. Researchers and physicians must guarantee that study findings are used to benefit patients and public health rather than for unethical purposes[87].

8.6 Equity and Access: It is vital to apply scientific results ethically. Researchers and physicians must ensure that study findings benefit patients and public health rather than being used for unethical purposes[87].

8.7 Research Integrity: It is critical for ethical clinical microbiology research to maintain research integrity by avoiding plagiarism, fabrication, and falsification of data[89].

8.8 Conflict of Interest: When financial interests or personal biases may influence research or diagnostic decision-making, ethical considerations arise. It is critical to be transparent when disclosing conflicts of interest[90].

Conclusion:

The intertwining of clinical microbiology and biomedical research represents a harmonious alliance aimed at enhancing our understanding of infectious diseases and improving patient care. The continuous exchange of knowledge and the development of innovative approaches ensure that the gap between the lab and the clinic is narrowing. With the ever-evolving landscape of healthcare, this synergy will remain pivotal in the fight against microbial infections and emerging diseases. The partnership between these two fields is a testament to the power of interdisciplinary collaboration in advancing medical science and safeguarding public health.

Funding
Nil

Author's contributions
All the authors have contributed equally.

Conflict of interest
None declared.

References:

1. Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, Hitchcock R, Walter T, D'souza MP. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. Journal of pharmaceutical and biomedical analysis. 2008 Jan 7;46(1):18-29.
2. Jarvis MF, Williams M. Irreproducibility in preclinical biomedical research: perceptions, uncertainties, and knowledge gaps. Trends in pharmacological sciences. 2016 Apr 1;37(4):290-302.
3. Pfaller MA, Herwaldt LA. The clinical microbiology laboratory and infection control: emerging pathogens, antimicrobial resistance, and new technology. Clinical infectious diseases. 1997 Oct 1:858-70.
4. Buchan BW, Ledeboer NA. Emerging technologies for the clinical microbiology laboratory. Clinical microbiology reviews. 2014 Oct;27(4):783-822.

5. Reller LB, Weinstein MP, Peterson LR, Hamilton JD, Baron EJ, Tompkins LS, Miller JM, Wilfert CM, Tenover FC, Thomson Jr RB. Role of clinical microbiology laboratories in the management and control of infectious diseases and the delivery of health care. Clinical infectious diseases. 2001 Feb 15;32(4):605-10.
6. Fournier PE, Drancourt M, Colson P, Rolain JM, Scola BL, Raoult D. Modern clinical microbiology: new challenges and solutions. Nature Reviews Microbiology. 2013 Aug;11(8):574-85.
7. Frickmann H, Masanta WO, Zautner AE. Emerging rapid resistance testing methods for clinical microbiology laboratories and their potential impact on patient management. BioMed research international. 2014 Oct;2014.
8. Vasala A, Hytönen VP, Laitinen OH. Modern tools for rapid diagnostics of antimicrobial resistance. Frontiers in Cellular and Infection Microbiology. 2020 Jul 15;10:308.
9. Uddin TM, Chakraborty AJ, Khusro A, Zidan BR, Mitra S, Emran TB, Dhama K, Ripon MK, Gajdács M, Sahibzada MU, Hossain MJ. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Journal of infection and public health. 2021 Dec 1;14(12):1750-66.
10. Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug resistance. Cell host & microbe. 2013 Jun 12;13(6):632-42.
11. Majumder MA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health. Infection and drug resistance. 2020 Dec 29:4713-38.
12. Silver LL, Bostian KA. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrobial agents and chemotherapy. 1993 Mar;37(3):377-83.
13. Li H, Wei W, Xu H. Drug discovery is an eternal challenge for the biomedical sciences. Acta Materia Medica. 2022 Jan 1.
14. Maruggi G, Ulmer JB, Rappuoli R, Yu D. Self-amplifying mRNA-based vaccine technology and its mode of action. InmRNA Vaccines 2021 Apr 17 (pp. 31-70). Cham: Springer International Publishing.
15. Cech TR. Fostering innovation and discovery in biomedical research. JAMA. 2005 Sep 21;294(11):1390-3.
16. National Research Council. (2011). Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease.
17. Vandenberg O, Durand G, Hallin M, Diefenbach A, Gant V, Murray P, Kozlakidis Z, van Belkum A. Consolidation of clinical microbiology laboratories and introduction of transformative technologies. Clinical microbiology reviews. 2020 Mar 18;33(2):10-128.
18. Mackenzie JS, Jeggo M, Daszak P, Richt JA, editors. One Health: The human-animal-environment interfaces in emerging infectious diseases. Berlin: Springer; 2013.
19. Archibald LK, Reller LB. Clinical microbiology in developing countries. Emerging infectious diseases. 2001 Mar;7(2):302.
20. Debnath M, Prasad GB, Bisen PS. Molecular diagnostics: promises and possibilities. Springer Science & Business Media; 2010 Jan 29.
21. Bakhtiar SM, Dilshad E, editors. Omics Technologies for Clinical Diagnosis and Gene Therapy: Medical Applications in Human Genetics. Bentham Science Publishers; 2022 Oct 3.
22. Wolman DM, Kalfoglou AL, LeRoy L. Technology trends in the clinical laboratory industry. InMedicare Laboratory Payment Policy: Now and in the Future 2000. National Academies Press (US).
23. Behlke MA, Berghof-Jäger K, Brown T. Polymerase chain reaction: theory and technology. Norfolk: Caister Academic Press; 2019 Jul.
24. Deurenberg RH, Bathoorn E, Chlebowicz MA, Couto N, Ferdous M, García-Cobos S, Kooistra-Smid AM, Raangs EC, Rosema S, Veloo AC, Zhou K. Application of next generation sequencing in clinical microbiology and infection prevention. Journal of biotechnology. 2017 Feb 10;243:16-24.
25. Gurtler V, Pavia CS. Immunological Methods in Microbiology. Academic Press; 2020 Apr 29.
26. Drancourt M, Michel-Lepage A, Boyer S, Raoult D. The point-of-care laboratory in clinical microbiology. Clinical microbiology reviews. 2016 Jul;29(3):429-47.
27. Darie-Ion L, Whitham D, Jayathirtha M, Rai Y, Neagu AN, Darie CC, Petre BA. Applications of

MALDI-MS/MS-based proteomics in biomedical research. Molecules. 2022 Sep 21;27(19):6196.
28. Berezsky O, Melnyk G, Batko Y. Modern trends in biomedical image analysis system design. Biomedical Engineering, Trends in Electronics, Communications and Software. 2011 Jan 8:461-80.
29. Xia F, Youcef-Toumi K. Advanced Atomic Force Microscopy Modes for Biomedical Research. Biosensors. 2022 Dec 2;12(12):1116.
30. List EO, Berryman DE, Bower B, Sackmann-Sala L, Gosney E, Ding J, Okada S, Kopchick JJ. The use of proteomics to study infectious diseases. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders). 2008 Mar 1;8(1):31-45.
31. Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. Bmj. 2017 Mar 15;356.
32. Iqbal MJ, Javed Z, Sadia H, Qureshi IA, Irshad A, Ahmed R, Malik K, Raza S, Abbas A, Pezzani R, Sharifi-Rad J. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer cell international. 2021 Dec;21(1):1-1.
33. Richardson LA. Understanding and overcoming antibiotic resistance. PLoS biology. 2017 Aug 23;15(8):e2003775.
34. Piddock LJ. Understanding the basis of antibiotic resistance: a platform for drug discovery. Microbiology. 2014 Nov;160(11):2366-73.
35. Cassell GH, Mekalanos J. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. Jama. 2001 Feb 7;285(5):601-5.
36. Larson EL, Saiman L, Haas J, Neumann A, Lowy FD, Fatato B, Bakken S. Perspectives on antimicrobial resistance: Establishing an interdisciplinary research approach. American journal of infection control. 2005 Sep 1;33(7):410-8.
37. Hughes D, Andersson DI. Environmental and genetic modulation of the phenotypic expression of antibiotic resistance. FEMS microbiology reviews. 2017 May 1;41(3):374-91.
38. Thomas AM, Raju LL, Khan SS. Omics and In Silico Approaches in the Surveillance and Monitoring of Antimicrobial Resistance. InEmerging Modalities in Mitigation of Antimicrobial Resistance 2022 Jan 31 (pp. 377-396). Cham: Springer International Publishing.
39. Sagar S, Kaistha S, Das AJ, Kumar R. Antibiotic Resistant Bacteria: A Challenge to Modern Medicine. Springer Singapore; 2019 Nov 14.
40. Boolchandani M, D'Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nature Reviews Genetics. 2019 Jun;20(6):356-70.
41. Punina NV, Makridakis NM, Remnev MA, Topunov AF. Whole-genome sequencing targets drug-resistant bacterial infections. Human genomics. 2015 Dec;9:1-20.
42. Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacological reviews. 2013 Jul 1;65(3):1053-90.
43. Dale JW, Park SF. Molecular genetics of bacteria. John Wiley & Sons; 2004 Mar 10.
44. Konai MM, Bhattacharjee B, Ghosh S, Haldar J. Recent progress in polymer research to tackle infections and antimicrobial resistance. Biomacromolecules. 2018 May 2;19(6):1888-917.
45. Brooks BD, Brooks AE. Therapeutic strategies to combat antibiotic resistance. Advanced drug delivery reviews. 2014 Nov 30;78:14-27.
46. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nature microbiology. 2019 Apr;4(4):565-77.
47. Wall S. Prevention of antibiotic resistance–an epidemiological scoping review to identify research categories and knowledge gaps. Global Health Action. 2019 Dec 13;12(sup1):1756191.
48. Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cellular & Molecular Immunology. 2021 Apr;18(4):805-28.
49. De Groot AS. Immunomics: discovering new targets for vaccines and therapeutics. Drug discovery today. 2006 Mar 1;11(5-6):203-9.
50. Woolhouse ME, Webster JP, Domingo E, Charlesworth B, Levin BR. Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nature genetics. 2002 Dec;32(4):569-77.
51. Adamczyk-Poplawska M, Markowicz S, Jagusztyn-Krynicka EK. Proteomics for development of vaccine. Journal of proteomics. 2011 Nov 18;74(12):2596-616.

52. Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021 Mar 18;184(6):1589-603.
53. Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. Vaccines. 2021 Dec 16;9(12):1490.
54. Sintchenko V, Gallego B. Laboratory-guided detection of disease outbreaks: three generations of surveillance systems. Archives of pathology & laboratory medicine. 2009 Jun 1;133(6):916-25.
55. Deng X, den Bakker HC, Hendriksen RS. Genomic epidemiology: whole-genome-sequencing–powered surveillance and outbreak investigation of foodborne bacterial pathogens. Annual review of food science and technology. 2016 Feb 28;7:353-74.
56. Tran A, Rowlinson MC. Application of next-generation sequencing in public health epidemiology and outbreak investigation. Advances in Molecular Pathology. 2019 Nov 1;2(1):89-97.
57. Hitchcock P, Chamberlain A, Van Wagoner M, Inglesby TV, O'Toole T. Challenges to global surveillance and response to infectious disease outbreaks of international importance. Biosecurity and bioterrorism: biodefense strategy, practice, and science. 2007 Sep 1;5(3):206-27.
58. Fauci AS. New and reemerging diseases: the importance of biomedical research. Emerging infectious diseases. 1998 Jul;4(3):374.
59. Yager P, Domingo GJ, Gerdes J. Point-of-care diagnostics for global health. Annu. Rev. Biomed. Eng.. 2008 Aug 15;10:107-44.
60. Giesecke J. Modern infectious disease epidemiology. CRC Press; 2017 May 8.
61. Monrad JT, Sandbrink JB, Cherian NG. Promoting versatile vaccine development for emerging pandemics. npj Vaccines. 2021 Feb 11;6(1):26.
62. Oli AN, Obialor WO, Ifeanyichukwu MO, Odimegwu DC, Okoyeh JN, Emechebe GO, Adejumo SA, Ibeanu GC. Immunoinformatics and vaccine development: an overview. ImmunoTargets and therapy. 2020 Feb 26:13-30.
63. Nelson MI, Lloyd-Smith JO, Simonsen L, Rambaut A, Holmes EC, Chowell G, Miller MA, Spiro DJ, Grenfell B, Viboud C. Fogarty International Center collaborative networks in infectious disease modeling: Lessons learnt in research and capacity building. Epidemics. 2019 Mar 1;26:116-27.
64. Pratt B, Bull S. Equitable data sharing in epidemics and pandemics. BMC medical ethics. 2021 Dec;22(1):1-4.
65. Pitt SJ, Sands RL. Effect of staff attitudes on quality in clinical microbiology services. British journal of biomedical science. 2002 Jan 1;59(2):69-75.
66. Pitt SJ. Managing for quality in clinical microbiology services. Liverpool John Moores University (United Kingdom); 2001.
67. Vodovotz Y, An G. Translational systems biology: concepts and practice for the future of biomedical research. Elsevier; 2014 Oct 8.
68. Flier JS, Loscalzo J. Categorizing biomedical research: the basics of translation. The FASEB Journal. 2017 Aug;31(8):3210.
69. Seals DR. Translational physiology: from molecules to public health. The Journal of physiology. 2013 Jul 15;591(14):3457-69.
70. Guin D, Thakran S, Singh P, Ramachandran S, Hasija Y, Kukreti R. Translational biotechnology: A transition from basic biology to evidence-based research. InTranslational Biotechnology 2021 Jan 1 (pp. 3-24). Academic Press.
71. Sun W, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. American Journal of Medical Genetics Part A. 2017 Sep;173(9):2307-22.
72. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. Clinical and translational science. 2011 Oct;4(5):332-7.
73. Field, M. J., & Lo, B. (Eds.). (2009). Conflict of interest in medical research, education, and practice.
74. Subramanyam M, Goyal J. Translational biomarkers: from discovery and development to clinical practice. Drug Discovery Today: Technologies. 2016 Sep 1;21:3-10.
75. McGaghie WC, Issenberg SB, Cohen ER, Barsuk JH, Wayne DB. Translational educational research: a necessity for effective health-care improvement. Chest. 2012 Nov 1;142(5):1097-103.
76. Rubio DM, Schoenbaum EE, Lee LS, Schteingart DE, Marantz PR, Anderson KE, Platt LD, Baez A, Esposito K. Defining translational research: implications for training. Academic medicine: journal of the Association of American Medical Colleges. 2010 Mar;85(3):470.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 196-207 | ISSN:2251-6727

77. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet infectious diseases. 2018 Mar 1;18(3):318-27.
78. Trovato M, Sartorius R, D'Apice L, Manco R, De Berardinis P. Viral emerging diseases: challenges in developing vaccination strategies. Frontiers in immunology. 2020 Sep 3;11:2130.
79. Moirongo RM, Aglanu LM, Lamshöft M, Adero BO, Yator S, Anyona S, May J, Lorenz E, Eibach D. Laboratory-based surveillance of antimicrobial resistance in regions of Kenya: an assessment of capacities, practices, and barriers by means of multi-facility survey. Frontiers in public health. 2022 Nov 28;10:1003178.
80. Reller LB, Weinstein MP, Peterson LR, Hamilton JD, Baron EJ, Tompkins LS, Miller JM, Wilfert CM, Tenover FC, Thomson Jr RB. Role of clinical microbiology laboratories in the management and control of infectious diseases and the delivery of health care. Clinical infectious diseases. 2001 Feb 15;32(4):605-10.
81. Carey RB, Bhattacharyya S, Kehl SC, Matukas LM, Pentella MA, Salfinger M, Schuetz AN. Practical guidance for clinical microbiology laboratories: implementing a quality management system in the medical microbiology laboratory. Clinical microbiology reviews. 2018 Jul;31(3):10-128.
82. Arellano AM, Dai W, Wang S, Jiang X, Ohno-Machado L. Privacy policy and technology in biomedical data science. Annual review of biomedical data science. 2018 Jul 20;1:115-29.
83. Desikan P, Chakrabarti A, Muthuswamy V. Ethical issues in microbiology. Indian Journal of Medical Microbiology. 2011 Oct 1;29(4):327-30.
84. Arellano AM, Dai W, Wang S, Jiang X, Ohno-Machado L. Privacy policy and technology in biomedical data science. Annual review of biomedical data science. 2018 Jul 20;1:115-29.
85. Beever J, Morar N. The porosity of autonomy: Social and biological constitution of the patient in biomedicine. The American Journal of Bioethics. 2016 Feb 1;16(2):34-45.
86. Green SK, Taub S, Morin K, Higginson D. Guidelines to prevent malevolent use of biomedical research. Cambridge Quarterly of Healthcare Ethics. 2006 Oct;15(4):432-9.
87. Lavery JV, editor. Ethical issues in international biomedical research: a casebook. Oxford University Press; 2007.
88. Mohan SV, Freedman J. A review of the evolving landscape of inclusive research and improved clinical trial access. Clinical Pharmacology & Therapeutics. 2023 Mar;113(3):518-27.
89. Yi N, Dierickx K, Nemery de Bellevaux B. Integrity in Biomedical Research in China.
90. Beckelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research. JaMa. 2003;289:454-65.